Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Bluejay Diagnostics ( (BJDX) ) is now available.
On June 3, 2025, Bluejay Diagnostics provided a mid-year business update, highlighting the initiation of the pivotal SYMON-II clinical study following the successful SYMON-I pilot study. The company is progressing towards a 510(k) submission for its Symphony IL-6 test by the fourth quarter of 2027, aiming for FDA approval by the third quarter of 2028. Bluejay is also addressing manufacturing challenges by collaborating with SanyoSeiko and exploring third-party manufacturing options. Financially, the company reported $5.7 million in cash as of April 30, 2025, and raised $3.8 million in April through private placement. To extend its cash runway, Bluejay has reduced its workforce and is seeking additional funding. The upcoming annual meeting on June 18, 2025, will address board restructuring and stock split proposals to maintain Nasdaq listing compliance.
Spark’s Take on BJDX Stock
According to Spark, TipRanks’ AI Analyst, BJDX is a Underperform.
Bluejay Diagnostics’ stock is heavily impacted by its poor financial performance, with no revenue and continuous losses. The technical indicators suggest a bearish trend, and valuation is challenging due to the negative P/E ratio. Improvements in equity are noted but overshadowed by the lack of profitability and revenue generation.
To see Spark’s full report on BJDX stock, click here.
More about Bluejay Diagnostics
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes through its Symphony System, which offers rapid, near-patient testing solutions for sepsis triage and monitoring. Their primary product candidate is the IL-6 Test, designed to provide quick and reliable results to aid medical professionals in making timely treatment decisions.
Average Trading Volume: 1,209,781
Technical Sentiment Signal: Sell
Current Market Cap: $2.63M
Find detailed analytics on BJDX stock on TipRanks’ Stock Analysis page.